EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Statin therapy and neuropathy in type 1 diabetes: A cross‐sectional study

Raabya Pasha iD, Anoushka Kamath, Zara Linn, Alise Kalteniece, Bilal Bashir, Jonathan D Schofield, Rayaz Malik iD, Shazli Azmi, Maryam Ferdousi, Handrean Soran iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16617 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Raabya Pasha und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetic Neuropathies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Dyslipidaemia contributes to the pathogenesis of diabetic peripheral neuropathy (DPN). While statins improve cardiovascular outcomes in diabetes, their potential neurotoxic effects remain debated. This study examined the impact of statin use on neuropathy in type 1 diabetes mellitus (T1DM). Materials and Methods Participants with T1DM ( n = 160) and healthy controls ( n = 64) underwent symptom and clinical evaluation of DPN, cardiac autonomic neuropathy (CAN) and corneal confocal microscopy (CCM). T1DM participants were stratified by statin use (non‐statin: n = 68; statin treated: n = 92).

Results

There were significant differences between the non‐statin and statin patients with T1DM and healthy controls for the diabetic neuropathy symptom score (DNS) (0.49 ± 0.14 vs. 0.90 ± 0.13 vs. 0.15 ± 0.13, p < 0.001), neuropathy disability score (NDS) (2.55 ± 0.29 vs. 3.67 ± 0.26 vs. 0.44 ± 0.28, p < 0.001), vibration perception threshold (13.68 ± 1.16 vs. 16.03 ± 1.03 vs. 6.05 ± 1.08, p < 0.001), corneal nerve fibre density (19.61 ± 1.04 vs. 19.02 ± 0.92 vs. 28.48 ± 0.97, p < 0.001), branch density (20.40 ± 2.21 vs. 21.39 ± 1.94 vs. 37.31 ± 2.05, p < 0.001), fibre length (11.97 ± 0.51 vs. 11.51 ± 0.45 vs. 16.55 ± 0.47, p < 0.001), DB‐HRV (26.27 ± 1.76 vs. 24.21 ± 1.51 vs. 30.18 ± 1.67, p = 0.033) and 30:15 ratio (1.32 ± 0.04 vs. 1.21 ± 0.03 vs. 1.15 ± 0.07, p = 0.033). Despite the statin group being significantly older ( p < 0.001) with a higher BMI ( p = 0.001) and longer duration of diabetes ( p < 0.001), statin‐treated patients showed no significant differences in most neuropathy measures, except DNS ( p = 0.04), NDS ( p = 0.009) and 30:15 ratio ( p = 0.04).

Conclusions

This study demonstrates that individuals with T1DM exhibit neuropathic symptoms and disability, increased vibration perception thresholds, corneal nerve fibre loss and evidence of CAN. However, statin therapy was associated with comparable measures of DPN and CAN, despite statin‐treated patients having a longer duration of diabetes and a higher BMI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetic NeuropathiesHydroxymethylglutaryl-CoA Reductase InhibitorsDyslipidemiasHumansMaleFemaleCross-Sectional StudiesAdultMiddle AgedCorneaCase-Control StudiesMicroscopy, Confocal

Stichwörter der Autor:innen

diabetic neuropathylipid‐lowering therapypaintype 1 diabetes

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Manchester University NHS Foundation Trust, Manchester, UK.
  • NIHR/Wellcome Trust Clinical Research Facility, Manchester, UK.
  • Department of Diabetes, Endocrinology and Metabolism, Manchester University NHS Foundation Trust, Manchester, UK.
  • Weill Cornell Medicine-Qatar, Doha, Qatar.

ORCID-Profile: Raabya Pasha, Rayaz Malik, Handrean Soran

Förderung

  • Wellcome Trust

Zitieren

APA

Pasha, R., Kamath, A., Linn, Z., Kalteniece, A., Bashir, B., Schofield, J. D., Malik, R., Azmi, S., Ferdousi, M., & Soran, H. (2025). Statin therapy and neuropathy in type 1 diabetes: A cross‐sectional study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16617

Vancouver

Pasha R, Kamath A, Linn Z, Kalteniece A, Bashir B, Schofield JD, et al. Statin therapy and neuropathy in type 1 diabetes: A cross‐sectional study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16617

BibTeX
@article{Pasha2025,
  author = {Pasha, Raabya and Kamath, Anoushka and Linn, Zara and Kalteniece, Alise and Bashir, Bilal and Schofield, Jonathan D and Malik, Rayaz and Azmi, Shazli and Ferdousi, Maryam and Soran, Handrean},
  title = {Statin therapy and neuropathy in type 1 diabetes: A cross‐sectional study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16617}
}
Kostenlos starten →